TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03836872

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Acupuncture
Description: Patients in the experimental group will receive, in addition to standard care, a standardised 30-minute acupuncture session needling specific acupoints although there will be flexibility in case some points cannot be punctured (e. g. in case of lymphoedema), and alternative points (as in routine practice) may be selected by the acupuncture practitioner using their discretion to maintain an equal dose of treatment to all patients. Bilateral acupoints will be stimulated. These points will include Waiguan (SJ5), Jianjing (GB21), Yanglingquan (GB34), Hegu (LI4), Jiexi (ST41) and Taixi (K3). In addition, joint specific acupoints will also be used, depending on where the joint symptoms are present.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Patients in the experimental group will receive, in addition to standard care, a standardised 30-minute acupuncture session needling specific acupoints although there will be flexibility in case some points cannot be punctured (e. g. in case of lymphoedema), and alternative points (as in routine practice) may be selected by the acupuncture practitioner using their discretion to maintain an equal dose of treatment to all patients. Bilateral acupoints will be stimulated. These points will include Waiguan (SJ5), Jianjing (GB21), Yanglingquan (GB34), Hegu (LI4), Jiexi (ST41) and Taixi (K3). In addition, joint specific acupoints will also be used, depending on where the joint symptoms are present.
Study: NCT00699946

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: olanzapine
Description: 5 mg preoperative and 5mg postoperative prior to discharge to inpatient nursing floor

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo administered preoperatively and postoperatively prior to discharge to inpatient nursing floor
Study: NCT01498744

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Clindamycin
Description: Based on our preliminary susceptibility data, oral clindamycin (10mg/kg up to 300 mg, every 8 hours) is the first line of antibiotic. Patients allergic or intolerant to clindamycin will receive oral trimethoprim-sulfamethoxazole \[bactrim\] (5mg/kg trimethoprim up to 160 mg, every 12 hours).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Clindamycin
Description: Based on our preliminary susceptibility data, oral clindamycin (10mg/kg up to 300 mg, every 8 hours) is the first line of antibiotic. Patients allergic or intolerant to clindamycin will receive oral trimethoprim-sulfamethoxazole \[bactrim\] (5mg/kg trimethoprim up to 160 mg, every 12 hours).
Study: NCT03308968

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fremanezumab
Description: Fremanezumab will be administered per dose and schedule specified in the arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fremanezumab
Description: Fremanezumab will be administered per dose and schedule specified in the arm.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fremanezumab
Description: Fremanezumab will be administered per dose and schedule specified in the arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matching to fremanezumab will be administered per schedule specified in the arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matching to fremanezumab will be administered per schedule specified in the arm.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching to fremanezumab will be administered per schedule specified in the arm.
Study: NCT04148053

Intervention type: DIAGNOSTIC_TEST
Intervention: TB-antigen responsive T cell markers
Description: A blood test including a series of T cell markers which are responsive to TB antigens

Intervention type: DIAGNOSTIC_TEST
Intervention: TB-antigen responsive T cell markers
Description: A blood test including a series of T cell markers which are responsive to TB antigens
Study: NCT01265368

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MGN1601
Description: Genetically modified allogeneic (human) tumor cells for the expression of IL-7, GM-CSF, CD80 and CD154, in fixed combination with a DNA-based double stem loop immunomodulator (dSLIM)
Study: NCT02330536

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Insufflation of carbon dioxide (CO2)
Description: After patients were positioned, CO2 was insufflated into right pleural cavity at eight or twenty L/min. during video-assisted thoracoscopic surgery, thoracic pressure, hemodynamic and respiratory parameters were recorded.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Insufflation of carbon dioxide (CO2)
Description: After patients were positioned, CO2 was insufflated into right pleural cavity at eight or twenty L/min. during video-assisted thoracoscopic surgery, thoracic pressure, hemodynamic and respiratory parameters were recorded.
Study: NCT03777254

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RC28-E
Description: RC28-E intravitreous injection 50ul
Study: NCT03346421

Intervention type: BEHAVIORAL
Intervention: diet and physical activity
Study: NCT02853396

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Behaviour Therapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation
Study: NCT04583436

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endovascular recanalization
Description: Recanalization with angioplasty and stenting: Under local anesthesia, a standard endovascular approach is performed and the affected arterial segment is visualized. Perform transluminal or subintimal recanalization of the occluded segment of the arteries with a hydrophilic guide wire. Next, balloon angoplasty of the recanalized segment is performed. After control angiography, a biomimetic braided nitinol stent is placed throughout the lesion.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Open surgery
Description: Femoropopliteal distal bypass with a synthetic ePTFE graft: Under general anesthesia, 2 standard open surgical approaches are performed: one to the common femoral artery, superficial femoral artery and deep femoral artery; the second - to the third portion of the popliteal artery, the tibioperoneal trunk and the anterior tibial artery. After systemic heparinization, clamps are applied to the arteries. A longitudinal arteriotomy of the popliteal artery is performed, and a distal end-to-side anastomosis is formed between the artery and the graft. Next, the graft is passed into the groin wound. Longitudinal arteriotomy of the common femoral artery. A proximal end-to-side anastomosis is formed between the shunt and the common femoral artery. Clamps are removed from arteries, blood flow is started, surgical hemostasis, wound drainage, layer-by-layer wound closure is performed.
Study: NCT03281031

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Additional MRI Examination
Description: MRI will be performed using a short protocol within 6 hours from CT and with blinding from CT results
Study: NCT01175876

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: remote limb ischemic preconditioning
Description: Remote limb ischemic preconditioning consisted of five 5-min cycles of right upper arm ischemia/reperfusion, which was induced by an automated cuff-inflator placed on the right upper arm which was inflated to 200 mmHg for 5mins followed by deflating the cuff for 5mins

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Carotid Artery Stenting
Description: Carotid Artery Stenting is an invasive therapy of carotid stenosis.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Carotid Artery Stenting
Description: Carotid Artery Stenting is an invasive therapy of carotid stenosis.
Study: NCT00812396

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: low dose testosterone
Description: Subjects will receive two muscle biopsies, the first at baseline, and the second a week after a single intramuscular dose of 200 mg (0.8 mL) testosterone.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: high dose testosterone
Description: Subjects will receive two muscle biopsies, the first at baseline, and the second a week after a single intramuscular dose of 600 mg (2.4 mL) testosterone.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: placebo
Description: Subjects will receive two muscle biopsies, the first at baseline, and the second a week after a single intramuscular dose of 0.8 mL placebo saline solution.
Study: NCT01067118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LINjeta U-100 Insulin
Description: LINjeta U-100 Insulin will be used per the subjects normal insulin carbohydrate and insulin sensitivity factors

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Humalog U-100
Description: Normal short acting insulin used in participants daily life including carbohydrate ratios and insulin sensitivity factors
Study: NCT03150550

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness practice
Description: Mindfulness interventions are behavioral cognitive psychotherapies which allow patient to identify, pay attention and accept external (sensory stimuli) and internal (cognition and emotions) phenomena.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relapse prevention
Description: It's a conventional relapse prevention program which allow to measure the alcoholic relapse in the first glass consumed.
Study: NCT02998684

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active Transcranial Direct Current Stimulation

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Transcranial Direct Current Stimulation

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PEERS Social Skills Training
Description: 14 weekly social skills training sessions for all participants

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: PEERS Social Skills Training
Description: 14 weekly social skills training sessions for all participants
Study: NCT03293290

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PrEP
Description: Subjects on PrEP will be followed for 1 year with quarterly assessments by trained research assistants. Study visits will take place at in New Haven and Hartford. At every scheduled visit, participants will receive a comprehensive package of preventive services, including a prescription for the next 30-day supply of TDF/FTC (with 2 refills), a symptom screen for acute HIV, risk-reduction counseling, PrEP adherence support, bleach for cleaning injection equipment, and condoms. HIV rapid testing with Orasure® will be performed quarterly; participants testing newly positive for HIV (representing seroconversions) will be followed with confirmatory testing and referred to care as needed.
Study: NCT00653575

Intervention type: BEHAVIORAL
Intervention: Information-Motivation-Behavioral Skills model
Description: The Information-Motivation-Behavioral Skills model is an influential and empirically supported theory of health behavior. The model suggests that HIV-related information, motivation, and behavioral skills are important determinants of sexual behavior; thus, childhood sexual abuse may lead to deficits in these areas. This model will be used to guide research interviews.
Study: NCT02735057

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Study: NCT04512677

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Timed Inspiratory Effort (TIE index)
Description: Conventional clinical treatment and using the Timed Inspiratory Effort (TIE index), which guided the decision to ventilate weaning and extubation.
Study: NCT03979469

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine, dexmedetomidine
Description: Patients will receive non-opioid analgesics, such as dexmedetomidine, ketamine perioperatively

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fentanyl, remifentanil
Description: Patients will receive opioid analgesics, such as fentanyl and remifentanil perioperatively
Study: NCT03080571

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous BMMNC stem cells
Description: Autologous BMMNC injected in the ipsilateral MCA

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard care

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard care
Study: NCT01050023

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Provant Device (Wound Therapy System)
Description: Twice daily application of the active Provant device to the wound for twelve (12) weeks.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Provant Device - Inactive
Description: Twice daily application of the inactive Provant device to the wound for twelve (12) weeks.
Study: NCT02110433

Intervention type: DEVICE
Group type: OTHER
Intervention: Placebo group
Description: patient will be managed as recommended by ESC guidelines and follow up will be in accordance to ESC recommendations

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cordiva System (R)
Description: Patients have to answer to 8 specific binary questions based on the main precipitating factors for decompensation and measure their body weight every day. If not they will be contact after two missing measures. Patient will be contact by phone call every month in order to reinforce the initial patient therapeutic education and patient-'s compliance. Patient have access to specific printed documents and to a specific web based platform where he can find some PowerPoint presentation on CHF aetiology, signs and therapy and where he can try to answer to monthly quiz in whom questions are based on key messages about CHF according to guidelines and consensus paper on patient therapeutic education.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cordiva System (R)
Description: Patients have to answer to 8 specific binary questions based on the main precipitating factors for decompensation and measure their body weight every day. If not they will be contact after two missing measures. Patient will be contact by phone call every month in order to reinforce the initial patient therapeutic education and patient-'s compliance. Patient have access to specific printed documents and to a specific web based platform where he can find some PowerPoint presentation on CHF aetiology, signs and therapy and where he can try to answer to monthly quiz in whom questions are based on key messages about CHF according to guidelines and consensus paper on patient therapeutic education.
Study: NCT00653575

Intervention type: BEHAVIORAL
Intervention: Information-Motivation-Behavioral Skills model
Description: The Information-Motivation-Behavioral Skills model is an influential and empirically supported theory of health behavior. The model suggests that HIV-related information, motivation, and behavioral skills are important determinants of sexual behavior; thus, childhood sexual abuse may lead to deficits in these areas. This model will be used to guide research interviews.

Intervention type: BEHAVIORAL
Intervention: Traumagenic Dynamics model
Description: The Traumagenic Dynamics model is an influential and empirically supported model of the effects of childhood sexual abuse. The model suggests that childhood sexual abuse leads to traumatic sexualization, stigmatization, betrayal, and powerlessness and that these four traumagenic dynamics lead to adverse outcomes, including increased rates of sexual risk behavior. This model will be used to guide research interviews.

Intervention type: BEHAVIORAL
Intervention: Traumagenic Dynamics model
Description: The Traumagenic Dynamics model is an influential and empirically supported model of the effects of childhood sexual abuse. The model suggests that childhood sexual abuse leads to traumatic sexualization, stigmatization, betrayal, and powerlessness and that these four traumagenic dynamics lead to adverse outcomes, including increased rates of sexual risk behavior. This model will be used to guide research interviews.
Study: NCT01841294

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Lidocaine
Description: Lidocaine infusion: 1.5 mg/kg bolus on 10 minutes (maximum 150 mg) followed by 1.5 mg/kg/h

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline infusion
Description: Normal saline infusion: 1.5 mg/kg bolus on 10 minutes (maximum 150 mg) followed by 1.5 mg/kg/h
Study: NCT04037007

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fistulotomy - High experienced.
Description: We will perform a duodenoscopy, once located next to the papilla, we will perform precut fistulotomy on the papillary infundibulum with a needle knife with EBRE, EndoCut I, Effect 2, until biliary fluid exit is seen or the biliary duct is noted, then we will access to the biliary tree to complete de procedure.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fistulotomy - Low experienced.
Description: We will perform a duodenoscopy, once located next to the papilla, we will perform precut fistulotomy on the papillary infundibulum with a needle knife with EBRE, EndoCut I, Effect 2, until biliary fluid exit is seen or the biliary duct is noted, then we will access to the biliary tree to complete de procedure.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional (guidewire) cannulation- High experienced
Description: We will perform a duodenoscopy, once located next to the papilla, we will perform cannulation with sphincterotome and hydrophilic tipped guidewire aided by fluoroscopy, once the guidewire reaches de common bile duct (seen on fluoroscopy) we will continue with the procedure according to the patient's indication.
Study: NCT03123458

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: clonal fetal MSCs
Study: NCT03870867

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT04023643

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ventilation Weaning
Description: Use of different weaning strategies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ventilation Weaning
Description: Use of different weaning strategies
Study: NCT01303757

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dietary counselling

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary counselling
Study: NCT01199679

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mucosectomy
Description: Endoscopic mucosal resection in the upper GI tract.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rubber Band Ligation
Description: Endoscopically ligate esophageal varices at or above the gastroesophageal junction or to ligate internal hemorrhoids.
Study: NCT01284621

Intervention type: DRUG
Group type: OTHER
Intervention: BI 10773
Description: medium dose, oral administration

Intervention type: DRUG
Group type: OTHER
Intervention: Ramipril
Description: Medium dose oral administration on day 2-5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773
Description: medium dose oral administration

Intervention type: DRUG
Group type: OTHER
Intervention: Ramipril
Description: Low dose oral administration on day 1

Intervention type: DRUG
Group type: OTHER
Intervention: Ramipril
Description: Low dose oral administration on day 1

Intervention type: DRUG
Group type: OTHER
Intervention: Ramipril
Description: Medium dose oral administration on day 2-5
Study: NCT04838548

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRG003
Description: Administered intravenously
Study: NCT02110433

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BNP heartcheck
Description: Patients had to measure the BNP plasma level using Alere home based BNP device heartcheck in a weekly basis in order to follow this parameter up. In case of clinical signs of CHF or a significant weight increase identified by the tele monitoring or the patient, the nurse will ask to the patient to do an extra measurement of home BNP testing in order to exclude a CHF decompensation (BNP \< 100 pg/ml or remaining stable (\< 30% increase).
Study: NCT04557878

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hypertonic Dextrose Solution
Description: Patients in this group will receive an intra-articular injection of 12.5% hypertonic dextrose solution, once every month for three consecutive months, in conjugation with a maxillary CAD/CAM full-arch hard clear acrylic stabilization appliance.The point of needle entry will be 1 cm below the apex of the zygomatic arch and guided by ultrasound to ensure intra-articular injection in the superior joint space.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Liquid Phase Concentrated Growth Factor (LPCGFs)
Description: Patients in this group will receive single intra-articular injection of LPCGF in conjugation with a maxillary CAD/CAM full-arch hard clear acrylic stabilization appliance.
Study: NCT00687323

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Study: NCT03329573

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paroxetine IR tablets A
Description: Paroxetine IR tablets A will be the investigational drug. These are film coated tablets with unit dose strength of 20 milligrams (mg) and will be administered via oral route. These tablets will be manufactured in GSKT.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paroxetine IR tablets A
Description: Paroxetine IR tablets A will be the investigational drug. These are film coated tablets with unit dose strength of 20 milligrams (mg) and will be administered via oral route. These tablets will be manufactured in GSKT.
Study: NCT03332238

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Autologous Stomal Vascular Fraction Material
Description: Autologous Stomal Vascular Fraction Material Prepared from the Tissue Genesis® Icellator Cell Isolation System™

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Ringer's solution
Description: Ringer's solution
Study: NCT01067287

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CT-011
Description: Infusions starting one to three months following autologous transplant at 6 week intervals for a total of 3 doses

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CT-011
Description: Infusions starting one to three months following autologous transplant at 6 week intervals for a total of 3 doses

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Dendritic Cell Fusion Vaccine
Description: One week following each infusion of CT-011
Study: NCT04037007

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional (guidewire) cannulation - Low experienced
Description: We will perform a duodenoscopy, once located next to the papilla, we will perform cannulation with sphincterotome and hydrophilic tipped guidewire aided by fluoroscopy, once the guidewire reaches de common bile duct (seen on fluoroscopy) we will continue with the procedure according to the patient's indication.